Genmab A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0010272202
DKK
1,693.50
21 (1.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

173.0 k

Shareholding (Dec 2025)

FII

0.04%

Held by 4 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 106,367 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.88

stock-summary
Return on Equity

18.89%

stock-summary
Price to Book

2.86

Revenue and Profits:
Net Sales:
6,789 Million
(Quarterly Results - Dec 2025)
Net Profit:
199 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.23%
0%
-20.23%
6 Months
-7.99%
0%
-7.99%
1 Year
24.89%
0%
24.89%
2 Years
-20.34%
0%
-20.34%
3 Years
-34.31%
0%
-34.31%
4 Years
-28.66%
0%
-28.66%
5 Years
-17.19%
0%
-17.19%

Genmab A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.34%
EBIT Growth (5y)
5.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.46
Tax Ratio
13.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
125.56%
ROE (avg)
18.85%

Valuation key factors

Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.96
EV to EBIT
16.21
EV to EBITDA
16.21
EV to Capital Employed
2.22
EV to Sales
5.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.67%
ROE (Latest)
18.89%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 4 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 5.40% vs 37.69% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -94.83% vs 500.78% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,788.70",
          "val2": "6,441.00",
          "chgp": "5.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,559.20",
          "val2": "2,191.00",
          "chgp": "-28.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "282.30",
          "val2": "54.00",
          "chgp": "422.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,187.10",
          "val2": "-31.00",
          "chgp": "-3,729.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "198.90",
          "val2": "3,845.00",
          "chgp": "-94.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "229.70%",
          "val2": "340.20%",
          "chgp": "-11.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 14.28% vs 30.67% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -18.81% vs 80.24% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24,600.40",
          "val2": "21,526.00",
          "chgp": "14.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,735.80",
          "val2": "7,416.00",
          "chgp": "17.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "403.40",
          "val2": "120.00",
          "chgp": "236.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,223.40",
          "val2": "-300.00",
          "chgp": "-307.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,368.30",
          "val2": "7,844.00",
          "chgp": "-18.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "336.00%",
          "val2": "325.30%",
          "chgp": "1.07%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
6,788.70
6,441.00
5.40%
Operating Profit (PBDIT) excl Other Income
1,559.20
2,191.00
-28.84%
Interest
282.30
54.00
422.78%
Exceptional Items
-1,187.10
-31.00
-3,729.35%
Consolidate Net Profit
198.90
3,845.00
-94.83%
Operating Profit Margin (Excl OI)
229.70%
340.20%
-11.05%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 5.40% vs 37.69% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -94.83% vs 500.78% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
24,600.40
21,526.00
14.28%
Operating Profit (PBDIT) excl Other Income
8,735.80
7,416.00
17.80%
Interest
403.40
120.00
236.17%
Exceptional Items
-1,223.40
-300.00
-307.80%
Consolidate Net Profit
6,368.30
7,844.00
-18.81%
Operating Profit Margin (Excl OI)
336.00%
325.30%
1.07%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 14.28% vs 30.67% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -18.81% vs 80.24% in Dec 2024

stock-summaryCompany CV
About Genmab A/S stock-summary
stock-summary
Genmab A/S
Pharmaceuticals & Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Coordinates stock-summary
Company Details
Kalvebod Brygge 43 , KOEBENHAVN V None : 1560
stock-summary
Tel: 45 7020272845 3 3779558
stock-summary
Registrar Details